Age-male-albumin-bilirubin-platelet score stratifies hepatocellular carcinoma risk after sustained virological response in hepatitis C-related compensated advanced chronic liver disease

Figure 3 Kaplan-Meier curves. A: Kaplan-Meier curves of hepatocellular carcinoma risk according to empirically derived age-male-albumin-bilirubin-platelet (aMAP) score strata. Patients were stratified into low-, intermediate-, and high-risk groups using thresholds of < 55, 55 to < 60, and ≥ 60, respectively; B: Kaplan-Meier curves of hepatocellular carcinoma risk according to the originally validated aMAP score strata. Patients were stratified into low-, intermediate-, and high-risk groups using thresholds of < 50, 50 to < 60, and ≥ 60, respectively. aMAP: Age-male-albumin-bilirubin-platelet score.